
NYSE:STZ
This summary was created by AI, based on 2 opinions in the last 12 months.
Constellation Brands Inc (STZ-N) is set to report earnings insights that highlight mixed perspectives from analysts. One expert expresses optimism, showcasing confidence in the newly appointed CEO and anticipating a positive shift in beer and cocktail sales. Conversely, another expert paints a more negative picture, noting that the broader alcohol industry, including Constellation, has struggled recently, facing challenges such as decreased sales driven by ICE raids in key shopping areas. This year, the stock has experienced a significant decline of 36%, with its current price-to-earnings ratio at a notably low 12x. While some view this low valuation as attractive, it is deemed justified due to ongoing weak sales and the emergence of competition from GLP-1 drugs. Overall, while there are signs of potential recovery, significant headwinds linger for Constellation Brands.
(A Top Pick Feb 24/16. Up 25%.) Switched out of this given that it was a consumer staples name, and into more of the cyclical areas. He still likes the name. Trading at 21X forward earnings with a 17% long-term growth rate. Sales going forward could be challenged by Pres. Trump’s potential policy to raise tariffs on Mexican imports.
This has a number of things in its favour right now. Technically it is in a distinct upward trend, outperforming the market with positive momentum, so the technicals are good. Seasonality is more important, because on a seasonal basis it historically reaches a very important low right around the middle of October, and moves higher right through until the middle of February.
This has had tremendous price momentum. It is really a consolidator of wineries and alcoholic beverages. Valuation is OK. Good ROE’s, a little expensive on EB to EBITDA and Price to Free Cash Flow. They have a decent balance sheet, so can continue their strategy of rolling up smaller competitors. Dividend yield of 1%. Not super cheap.